Yttrium (90Y) tacatuzumab tetraxetan: Difference between revisions
Appearance
Content deleted Content added
m →References: clean up - nav using AWB |
Luckas-bot (talk | contribs) m r2.7.1) (robot Adding: it:Tacatuzumab tetraxetan |
||
Line 44: | Line 44: | ||
{{monoclonal-antibody-stub}} |
{{monoclonal-antibody-stub}} |
||
[[it:Tacatuzumab tetraxetan]] |
Revision as of 10:03, 28 March 2011
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Humanized (from mouse) |
Target | α-fetoprotein |
Clinical data | |
ATC code |
|
Identifiers | |
CAS Number | |
Chemical and physical data | |
Formula | C6470H9971N1712O2007S4290Y |
Molar mass | 145 kDa |
Yttrium (90Y) tacatuzumab tetraxetan (trade name AFP-Cide) is a humanized monoclonal antibody intended for the treatment of cancer.[1] The antibody itself, tacatuzumab, is conjugated with a chelator for yttrium-90[2], a radioisotope which destroys the tumour cells.
The chelator ("tetraxetan") is 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid. The antibody is attached to one of the four carboxyl groups as an amide, and the other three are carboxylate anions neutralizing the three positive charges of the yttrium ion.
References